Phase I-II Study of Capecitabine and Oxaliplatin in Combination With Radiotherapy in Patients With Unresectable Gastro-Intestinal Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Anders Johnsson, MD, PhD
Principal Investigator
University Hospital Lund
Sweden: Medical Products Agency
Version1
NCT01016639
June 2003
July 2009
Name | Location |
---|